

Notice of Allowability

Application No.

10/759,985

Applicant(s)

SCHINAZI ET AL.

Examiner

Art Unit

L. E. Crane

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed October 15, 2007.
2. ☒ The allowed claim(s) is/are 12,14,15 and 17-33.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date 11192007
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material

5. ☐ Notice of Informal Patent Application
6. ☒ Interview Summary (PTO-413),
Paper No./Mail Date 01042008
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.


L. E. Crane, Ph.D., Esq.
Primary Patent Examiner
Technology Center 1600

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. §1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

The disclosure was amended as follows:

At page 2, line 33, the term "canc r" was amended to read
-- cancer --.

At page 2, line 34, the term "b en" was amended to read
-- been --.

At page 3, line 35, the term "Whil" was amended to read
-- While -- .

At page 4, line 34, the term "structur" was amended to read
-- structure --.

At page 8, line 30, the term "includ" was amended to read
-- include --.

At page 8, line 32, the term "th" was amended to read
-- the --.

At page 8, line 34, the term "int rf ron" was amended to read
-- interferon --.

At page 9, line 34, the term -- acceptabl" was amended to read
-- acceptable -- .

At page 10, line 33, the term "Th" was amended to read
-- The --.

At page 10, line 33, the term "pharmac utically" was amended to read
-- pharmaceutically --.

At page 12, line 34, the term "th" was amended to read
-- the --.

At page 13, line 33, the term "asily" was amended to read
-- easily --.

At page 13, line 34, the term "th" was amended to read
-- the --.

At page 14, line 33, the term " d." was amended to read
-- ed. --.

At page 15, line 19, thge term "nuclei" was amended to read
-- nucleic --.

At page 15, at line 32, the term "dichloroethan" was amended to read
-- dichloroethane --.

At page 15, at line 33, the terms "provid", "th " and "pur" were amended to read
-- provide --, --the -- and -- pure --, respectively.

At page 15, at line 34, the term "dioxolan -nucleosid " was amended to read
-- dioxolane-nucleoside -- .

At page 17, at line 33, the term "w r" was amended to read
-- were --.

At page 17, at line 34, the term "Enzym" was amended to read
-- Enzyme --.

At page 20, at line 36, the term "th" was amended to read
-- the --.

At page 20, at line 37, the term "revers" was amended to read
-- reverse --.

At page 21, at line 31, the term "Tabl" was amended to read
-- Table --.

At page 21, at line 32, the term "th" was amended to read
-- the --.

At page 21, at line 32, the term "valu s" was amended to read
-- values --.

At page 21, at line 34, the term "th" was amended to read
-- the --.

At page 24, at line 1, the term "Exampl " was amended to read
-- Example --.

At page 24, at line 6, the term "b low" was amended to read
-- below --.

At page 24, at line 31, the term "equivalenc" was amended to read
-- equivalence --.

At page 27, at line 11, the term "r latively" was amended to read
-- relatively --.

At page 29, at line 24, the term "r cipient" was amended to read
-- recipient --.

At page 29, at line 27, the term "d rivative" was amended to read
-- derivative --.

At page 29, at line 28, the term " b " was amended to read
-- be --.

At page 29, at line 32, the terms “ activ ” and “p r” were amended to read
-- active -- and -- per --, respectively.

At page 30, at line 29, the term “ th ” was amended to read
-- the --.

At page 30, at line 33, the term “ bind r ” was amended to read
-- binder --.

At page 30, at line 33, the term “ microcrystallin cellulos ” was amended to read
-- microcrystalline cellulose --.

At page 31, at line 32, the term “ mad ” was amended to read
-- made --.

At page 32, at line 31, the term “ intend d ” was amended to read
-- intended --.

At page 32, at line 32, the terms “ thes” and “ b ” were amended to read
-- these -- and -- be --, respectively.

Authorization for this Examiner’s Amendment was not necessary because the corrections are minor and typographical in nature and said errors therefore do not effect the scope of disclosed or claimed subject matter.

The following is an Examiner’s Statement of Reasons for Allowance:

Examiner notes the acceptance of applicant’s submitted terminal disclaimer and applicant’s amendments to the claims, the consequence of which has been to render the instant rejections of record moot. For this reason the instant claims have been found to be allowable.

Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”

Papers related to this application may be submitted to Group 1600 via facsimile transmission (FAX). The transmission of such papers must conform with the notice published in the Official Gazette (1096 OG 30, November 15, 1989). The telephone number to FAX (unofficially) directly to Examiner's computer is 571-273-0651. The telephone number for sending an Official FAX to the PTO is 571-273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner L. E. Crane whose telephone number is **571-272-0651**. The examiner can normally be reached between 9:30 AM and 5:00 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. S. Anna Jiang, can be reached at **571-272-0627**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is **571-272-1600**.

All Post-Allowance Correspondence concerning this application must be mailed to:

BOX ISSUE FEE
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

OR you can FAX them to the Office of Patent Publications at 571-273-8300, in order to expedite the handling of such correspondence as amendments under 37 C.F.R. §1.312; Information Disclosure Statements (IDS's), and formal drawings. Sending Post-Allowance papers to Technology Center 1600 will only cause delays in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence Branch at **571-272-4200**. The Notice of Allowance also has an insert containing contact information for other items, including Issue Fees, receipt of formal drawings, and the status of the application.

Application/Control Number:
10/759,985
Art Unit: 1623

Page 7

LECrane:lec
01/04/2008

A handwritten signature in black ink, appearing to read "L. E. Crane", is written over a horizontal line.

L. E. Crane, Ph.D., Esq.
Primary Patent Examiner
Technology Center 1600